Tanguy Y. Seiwert
唐吉·赛韦特
MD
Associate Professor of Oncology肿瘤学副教授
👥Biography 个人简介
Tanguy Seiwert is a clinical oncologist and translational researcher renowned for his leadership of the first pembrolizumab trial in head and neck cancer. His work at University of Chicago and subsequently at Johns Hopkins has been instrumental in establishing immunotherapy as a pillar of HNSCC treatment.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
First-in-Human Pembrolizumab
Led KEYNOTE-012, the first trial of pembrolizumab in HNSCC patients, generating landmark safety and efficacy data that led to accelerated FDA approval.
Biomarker Research
Developed PD-L1 and tumor mutational burden biomarker frameworks for predicting immunotherapy response in HNSCC, advancing precision oncology.
Representative Works 代表性著作
Antitumour Activity of Pembrolizumab in Biomarker-Unselected Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Annals of Oncology (2016)
KEYNOTE-012 expansion cohort demonstrating consistent pembrolizumab activity across PD-L1 subgroups in HNSCC.
Concurrent Cetuximab, Cisplatin, and Concomitant Boost Radiation for Locoregionally Advanced, Non-Operated Head and Neck Squamous Cell Carcinoma
Annals of Oncology (2008)
Established safety and activity of triple-modality approach in LA-HNSCC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Robert L. Ferris
University of Pittsburgh Medical Center
David J. Adelstein
Cleveland Clinic Taussig Cancer Institute
Maura L. Gillison
MD Anderson Cancer Center
Kevin J. Harrington
Royal Marsden NHS Foundation Trust / Institute of Cancer Research
关注 唐吉·赛韦特 的研究动态
Follow Tanguy Y. Seiwert's research updates
留下邮箱，当我们发布与 Tanguy Y. Seiwert（Johns Hopkins Sidney Kimmel Comprehensive Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment